DOV Pharmaceutical
DOV Pharmaceutical, was a biotechnology company that focused on therapies primarily for central nervous system conditions. It was founded in 1995 by former employees of American Cyanamid (which was acquired by Wyeth in 1994), and in 1998 it in-licensed drugs discovered at American Cyanamid for further development.[1]:454 It held an IPO on NASDQ in 2002,[2] and its shares plunged days later after negative details about a past relationship between Élan and DOV emerged.[3][4][5][6]
After several failed clinical trials, in 2010 Dov was acquired by Euthymics Bioscience which intended to continue development of Dov's antidepressant, DOV 21,947 (renamed EB-1010).[7]
Its drug candidates included:
- Indiplon for insomnia, licensed from Wyeth in 1998, which it licensed to Neurocrine Biosciences in 1998.[1]
- Bicifadine, a triple-uptake inhibitor for pain, licensed from Wyeth in 1998,[8][9]
- Triple-uptake inhibitors for depression and related psychiatric disorders: (DOV 21,947 and DOV 216,303) licensed from Wyeth in 1998.[8] Merck sublicensed the rights in 2004,[10] and terminated them in 2006.[11]
- Ocinaplon for anxiety disorders.[12]
- A proprietary formulation of diltiazem[12]
- DOV 102,677, for the treatment of Parkinson's disease, restless leg syndrome, attention deficit disorder[12]
- DOV 51,892, for anxiety disorders[12]
References
- 1 2 Neubauer, DN. "Indiplon". pp 453-464 in GABA and Sleep: Molecular, Functional and Clinical Aspects. Eds Jaime M. Monti, Seithikurippu Ratnas Pandi-Perumal, Hanns Möhler. Springer Science & Business Media, 2010 ISBN 9783034602266
- ↑ Edgar Online. IPO Deal Data Page accessed July 15, 2015
- ↑ Hess, Diane, Drugmaker's IPO Is a Big Headache, TheStreet.com, 1 May 2002. Retrieved 5 November 2007.
- Simpson, Stephen D. A Pain DOV Pharmaceutical Couldn't Cure, Motley Fool, 26 April 2006. Retrieved 5 November 2007.
- ↑ Krauskopf, Lewis, Investors Suing Hackensack, N.J.-Based DOV Pharmaceutical over Stock Losses, The Record (Hackensack, New Jersey), 2 May 2002. Retrieved 5 November 2007
- ↑ Maeillo, Michael, The Coldest IPO..., Forbes.com, 2 September 2002. Retrieved 5 November 2007
- ↑ DOV IPO sinks on first day, CNN.com, 25 April, 2002. Retrieved 5 November 2007
- ↑ Fierce Biotech July 22, 2010 Euthymics lands $24M to fund antidepressant work
- 1 2 Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: a premise and promise. Psychiatry Investig. 2008 Sep;5(3):142-7. PMID 20046357 PMC2796030
- ↑ [http://www.sec.gov/Archives/edgar/data/1066833/000114420404018172/v08017_ex10-51.txt SEC Filing: Wyeth-DOV Restated License Agreement Page accessed July 15, 2015]
- ↑ Chemical and Engineering News. August 12, 2004 Merck and DOV Pharmaceutical In Drug Pact
- ↑ Dov December 8, 2006 DOV Pharmaceutical Announces Termination Of License Agreement With Merck & Co., Inc. (MRK)
- 1 2 3 4 Edgar Online. Data as of May 2004 IPO Deal Data: Business Description Page accessed July 15, 2015
External links
-
- Business data for DOV Pharmaceutical Inc.:
- Hoover's
- Reuters
- SEC filings
This article is issued from Wikipedia - version of the Saturday, November 28, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.